Neuronetics (STIM) Set to Announce Earnings on Tuesday

Neuronetics (NASDAQ:STIM) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Neuronetics (NASDAQ:STIM) last announced its quarterly earnings results on Tuesday, March 5th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.07. Neuronetics had a negative net margin of 42.31% and a negative return on equity of 72.76%. The firm had revenue of $20.31 million for the quarter, compared to analyst estimates of $19.73 million. During the same quarter in the previous year, the firm posted ($0.30) earnings per share. On average, analysts expect Neuronetics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Neuronetics Trading Up 8.9 %

Shares of STIM stock opened at $3.81 on Monday. Neuronetics has a 12-month low of $1.03 and a 12-month high of $5.07. The company has a debt-to-equity ratio of 1.73, a current ratio of 4.73 and a quick ratio of 4.33. The firm has a fifty day moving average of $3.96 and a 200-day moving average of $2.93.

Insider Activity

In related news, CEO Keith J. Sullivan sold 23,958 shares of the firm’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $2.96, for a total value of $70,915.68. Following the completion of the transaction, the chief executive officer now owns 1,434,171 shares of the company’s stock, valued at $4,245,146.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CEO Keith J. Sullivan sold 23,958 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $2.96, for a total transaction of $70,915.68. Following the completion of the transaction, the chief executive officer now directly owns 1,434,171 shares of the company’s stock, valued at $4,245,146.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP William Andrew Macan sold 15,621 shares of the company’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $3.38, for a total value of $52,798.98. Following the sale, the executive vice president now owns 417,736 shares in the company, valued at approximately $1,411,947.68. The disclosure for this sale can be found here. Insiders have sold 150,279 shares of company stock worth $489,167 over the last ninety days. Insiders own 9.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. William Blair reiterated a “market perform” rating on shares of Neuronetics in a report on Tuesday, March 26th. Piper Sandler reiterated an “overweight” rating and set a $8.00 price objective (up from $7.00) on shares of Neuronetics in a report on Wednesday, March 6th.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.